Department of Justice Reclassifies State Licensed Medical Marijuana to Schedule III Under New Federal Order

The DOJ reclassifies medical marijuana to Schedule III, allowing tax breaks and new research. Discover how this impacts state licensed businesses.

By: AXL Media

Published: Apr 24, 2026, 4:42 AM EDT

Source: Information for this report was sourced from Maryland Matters

The Immediate Shift in Federal Narcotics Classification

In a major departure from long standing federal drug policy, the U.S. Department of Justice has officially downgraded the classification of state licensed medicinal marijuana. Acting Attorney General Todd Blanche issued the order on Thursday, shifting these products from Schedule I, a category reserved for the most dangerous substances with no accepted medical use, to the less restrictive Schedule III. This move specifically targets products regulated by state medical licenses and those with FDA approval, signaling a federal recognition of the legitimacy of state managed medical cannabis programs.

Regulatory Impacts and Tax Implications for Businesses

The reclassification provides an immediate and substantial financial shift for state licensed cannabis operators. Under the previous Schedule I status, businesses were barred from deducting standard operating expenses from their federal taxes under Section 280E of the internal revenue code. By moving to Schedule III, medical marijuana companies can now access tax deductions available to other legal industries, potentially saving the sector millions in annual liabilities. Despite this change, the order does not resolve the banking crisis for the industry, as financial institutions remain wary of federal money laundering charges for serving businesses that still technically violate certain federal statutes.

Expanding the Scope of Clinical and Scientific Research

One of the primary strategic goals of the rescheduling is to dismantle the barriers that have historically stifled cannabis research. Under the new guidelines, researchers are no longer restricted to using only marijuana grown at federally authorized facilities. They may now obtain state legal products for study, which Acting Attorney General Todd Blanche stated will provide doctors with more reliable information regarding the safety and efficacy of the substance. This change is expected to accelerate the development of standardized medical treatments and provide a clearer understanding of the drug’s long term health impacts.